KTT-1

KTT-1 is a kinetically selective and orally active HDAC2 inhibitor. KTT-1 exhibits high HDAC2-selectivity over HDAC1. KTT-1 inhibits osteoclast differentiation at an early stage by downregulating c-Fos expression. KTT-1 effectively suppresses arthritis symptoms in the collagen-induced arthritis (CIA) mouse model. KTT-1 can be used for the research of rheumatoid arthritis and neurodegenerative diseases[1][2].

Product Specifications

CAS Number

[2397562-26-2]

UNSPSC

12352005

Target

HDAC

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology; Neurological Disease

Smiles

O=C(NC1=CC(C2=CC=CO2)=CC=C1N)C(C=C3)=CC=C3C(N=N4)=CN4CS(=O)(C5=CC=CC=C5)=O

Molecular Formula

C26H21N5O4S

Molecular Weight

499.54

References & Citations

[1]Yumi Ogihara, et al. The HDAC2-selective inhibitor KTT-1 attenuates autoimmune arthritis by inhibiting osteoclast differentiation in mice. bioRxiv. October 21, 2025.|[2]Mishima H, et al. Origin of the kinetic HDAC2-selectivity of an HDAC inhibitor. J Comput Chem. 2023;44 (18) :1604-1609.